Amgen presents Prolia data at ASBMR medical conference

Amgen has attended a recent medical conference in order to highlight new clinical trial data on its osteoporosis treatment Prolia.

The company was present at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting, where it gave three presentations on the advantages of the denosumab-based therapy.

Among the benefits highlighted was its efficacy in promoting femoral and vertebral strength in female patients, as well as its ability to deliver density and mineral content improvements in integral, trabecular and cortical bone.

Other presentations given by Amgen at the event detailed the healthcare and economic impact of osteoporosis and other bone conditions.

Dr Catherine Stehman-Breen, vice-president of global development at Amgen, said this data illustrates the "continued need to reduce fractures caused by postmenopausal osteoporosis".

This comes after the company published clinical data earlier this month demonstrating the advantages Prolia treatment offers compared to the current standard of care.